Benchmark of BINN, GraphPath, and PATH on 2622 TCGA patients shows PATH best for targeted therapy, BINN for survival, none useful for radiation, with GraphPath at 0.92 AUROC on prostate targeted therapy.
Title resolution pending
3 Pith papers cite this work. Polarity classification is still indexing.
3
Pith papers citing it
years
2026 3verdicts
UNVERDICTED 3representative citing papers
Introduces symmetry-aware convex shrinkage for high-dimensional covariance estimation by selecting a symmetry group via held-out negative log-likelihood and proving regret bounds plus dominance over Ledoit-Wolf under a match condition.
SCOPE implements a relaxed sparsest-permutation approach for scalable causal structure learning that recovers Markov equivalence classes up to 10k variables using incomplete Cholesky factorization on screened supports.
citing papers explorer
-
Relaxed Sparsest-Permutation Formulation for Causal Discovery at Scale
SCOPE implements a relaxed sparsest-permutation approach for scalable causal structure learning that recovers Markov equivalence classes up to 10k variables using incomplete Cholesky factorization on screened supports.